Full data announced in phase III EMPA-KIDNEY trial
The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)
AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
Our family-owned company condemns the ongoing military aggression against Ukraine, and have maintained our support for those in need by providing financial and in-kind donations through our Boehringer Ingelheim Cares Foundation.